Brinzolamide

DRUG4 trials

Sponsors

Region Vaesterbotten, Beacon Therapeutics (USA) Inc., Peking University First Hospital, University of Miami

Conditions

GlaucomaOcular HypertensionX-linked retinitis pigmentosa (XLRP)open-angle and PEX glaucoma

Phase 3

Stop Retinal Ganglion Cell Dysfunction Study

TerminatedNCT02390284

University of MiamiGlaucoma

Start: 2015-09-30End: 2024-10-04Updated: 2025-08-26

A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa

WithdrawnCTIS2024-511181-36-00

Beacon Therapeutics (USA) Inc.X-linked retinitis pigmentosa (XLRP)

Target: 5Updated: 2024-09-17

Phase 4

Glaucoma Intensity Treatment Study – Intensive non-invasive glaucoma treatment vs conventional stepwise treatment – a prospective, randomized phase IV study of disease progression in glaucoma

Active, not recruitingCTIS2023-510041-16-00

Region VaesterbottenGlaucoma, open-angle and PEX glaucoma

Start: 2013-04-22Target: 240Updated: 2024-05-16

Unknown Phase

Efficacy Comparison of Xalatan and Azopt on POAG and OH

Peking University First HospitalOcular Hypertension

Start: 2010-02-28End: 2010-12-31Updated: 2010-03-11